Am Fam Physician. 1998;58(5):1084
Table 1 of the article “Combination Anti-retroviral Therapy for HIV Infection” (June 1998, p. 2791) contained an editing error. Dosing recommendations for zalcitabine (ddC: Hivid) would only include a dose reduction for weight under 60 kg in patients who have developed peripheral neuropathy attributed to zalcitabine therapy. Table 4 of the same article also contained an error. The Invirase formulation of saquinavir should not have been included. The corrected table is reprinted here.
| Preferred initial regimen | |
| Two nucleoside analogs + a highly active protease inhibitor, such as ritonavir (Norvir), indinavir (Crixivan), nelfinavir (Viracept) or saquinavir (Fortovase) | |
| Alternative initial regimens | |
| Two nucleoside analogs + a nonnucleoside reverse transcriptase inhibitor | |
| Two nucleoside analogs + saquinavir | |
| Two nucleoside analogs (although not generally recommended) | |
| Regimens not recommended | |
| Monotherapy | |
| Stavudine (Zerit) + zidovudine (Retrovir) | |
| Zalcitabine (Hivid) + didanosine (Videx) | |
| Zalcitabine + stavudine | |
| Zalcitabine + lamivudine (Epivir) | |
| Suggested regimens for patients who fail to respond to initial therapy | |
| • If initial regimen was two nucleoside analogs and a protease inhibitor, change to one of the following: | |
| Two different nucleoside analogs + a different protease inhibitor | |
| Two different nucleoside analogs + a protease inhibitor combination | |
| Two different nucleoside analogs + a protease inhibitor + a nonnucleoside reverse transcriptase inhibitor | |
| • If initial regimen was two nucleoside analogs and a nonnucleoside reverse transcriptase inhibitor, change to the following: | |
| Two different nucleoside analogs + a protease inhibitor | |
| • If initial regimen was two nucleoside analogs, change to the following: | |
| Two different nucleoside analogs + a protease inhibitor | |
| • If initial regimen was one nucleoside analog, change to one of the following: | |
| Two different nucleoside analogs + a protease inhibitor | |
| Two different nucleoside analogs + a nonnucleoside reverse transcriptase inhibitor | |